NKG7 mRNA-transfected T cells

NKG7 mRNA-transfected T cells is an experimental cell-based immunotherapy developed by researchers at the Mayo Clinic. The therapy involves the non-viral engineering of human T cells, specifically CD8+ cytotoxic T cells, by transfecting them with messenger RNA (mRNA) encoding the natural killer cell granule protein-7 (NKG7). NKG7 is a cytolytic granule-associated protein essential for T-cell antitumor cytotoxicity, playing a key role in granule trafficking and calcium release. By overexpressing NKG7, the therapy aims to enhance the intrinsic tumor-killing capacity of T cells, particularly in solid tumors like melanoma. Preclinical studies have demonstrated that this approach can restore the cytolytic function of T cells from patients who previously failed to respond to immune checkpoint inhibitors (anti-PD-1/PD-L1). The manufacturing process utilizes rapid, non-viral transfection methods such as electroporation or mechanoporation, potentially allowing for same-day, bedside production.

Other names

NKG7-transfected T cellsNKG-7-transfected T cellsNKG 7-transfected T cellsNKG7 mRNA-engineered T cellsNKG-7 mRNA-engineered T cellsNKG 7 mRNA-engineered T cellsNKG7-modified CD8+ T cells